Targets › ERBB3
12 programs from 10 companies in 32 trials: 16 Phase 1, 14 Phase 2, 2 Phase 3; Oncology, Cardiovascular; next expected readout Dec 2026.
Tyrosine kinase receptor that, despite substitutions of key catalytic residues in the kinase domain, retains residual catalytic activity enabling autophosphorylation. Functions primarily as a heterodimer, preferentially partnering with ERBB2/HER2, which phosphorylates ERBB3 on specific tyrosine residues and provides the kinase activity required for downstream signaling. (UniProt, P21860)
Open in Phaseline: the race on ERBB3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Daiichi Sankyo | Patritumab Deruxtecan Receptor tyrosine-protein kinase erbB-3 binding agent; DNA topoisomerase I inhibitor | ERBB3, TOP1 | Phase 3 | Nonsquamous Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer Metastatic; Advanced Solid Tumor; Non-Small Cell Lung Cancer (NSCLC) … | Dec 2026 |
| Merck & Co. (MSD) | Patritumab Deruxtecan Receptor tyrosine-protein kinase erbB-3 binding agent; DNA topoisomerase I inhibitor | ERBB3, TOP1 | Phase 3 | Breast Neoplasms; Non-small Cell Lung Cancer; Gastroesophageal Junction; Gastrointestinal Cancer … | May 2028 |
| Partner Therapeutics | Zenocutuzumab (MCLA-128) ErbB-2/ErbB-3 heterodimer inhibitor | ERBB2, ERBB3 | Phase 2 | Solid Tumours Harboring NRG1 Fusion | Dec 2026 |
| Fudan University | SHR-A2009 HER3-directed antibody-drug conjugate | ERBB3 | Phase 2 | Advanced Breast Cancer | Sep 2027 |
| Roswell Park Cancer Institute | Anti-HER2/HER3 Dendritic Cell Vaccine Dendritic cell vaccine targeting HER2 and HER3 | ERBB2, ERBB3 | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8 | May 2028 |
| Salubris Biotherapeutics | JK07 Anti-HER3 antibody fused with EGF-domain of Neuregulin-1b | ERBB3 | Phase 2 | Heart Failure With Reduced Ejection Fraction | – |
| Shanghai Institute Of Biological Products | SIBP-03 HER3 monoclonal antibody | ERBB3 | Phase 2 | Head and Neck Squamous Cell Carcinoma | – |
| UNICANCER | Sapitinib (AZD8931) Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor tyrosine-protein kinase erbB-3 inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ERBB2, ERBB3, EGFR | Phase 2 | Metastatic Breast Cancer | – |
| Hummingbird Bioscience | HMBD-501 HER3-targeted antibody-drug conjugate | ERBB3 | Phase 1 | Melanoma (Skin) | Jul 2027 |
| Hummingbird Bioscience | HMBD-001 Anti-HER3 monoclonal antibody | ERBB3 | Phase 1 | Advanced or Metastatic Squamous Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Bladder Cancer | Dec 2027 |
| Herbert Lyerly | pING-hHER3FL Plasmid DNA vaccine encoding full-length human HER3 (ErbB3) protein | ERBB3 | Phase 1 | Advanced Cancer | Mar 2030 |
| Shanghai Institute Of Biological Products | SIBP-A13 HER3-targeting antibody-drug conjugate | ERBB3 | Phase 1 | Advanced Solid Tumor | – |
Breast Neoplasms (3) Advanced Solid Tumor (2) Non-Small Cell Lung Cancer (NSCLC) (2) Metastatic Breast Cancer (2) Gastroesophageal Junction (2) Nonsquamous Non-small Cell Lung Cancer (1) Non-Small Cell Lung Cancer Metastatic (1) Hormone Receptor Positive (1) Heart Failure With Reduced Ejection Fraction (1) Head and Neck Squamous Cell Carcinoma (1) Melanoma (Skin) (1) Non-small Cell Lung Cancer (1)
small molecule (4), mixed (4), antibody (2), protein or peptide (2)
Shanghai Institute Of Biological Products (2) Hummingbird Bioscience (2) Daiichi Sankyo (1) Salubris Biotherapeutics (1) UNICANCER (1) Merck & Co. (MSD) (1) Partner Therapeutics (1) Roswell Park Cancer Institute (1) Fudan University (1) Herbert Lyerly (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.